| Name | Rosuvastatin |
| Description | Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects. |
| In vitro | METHODS: Microglia cultures subDIV were treated with Rosuvastatin (1 µM) and LPS (20 ng/mL) for 24 h, and cell counts were measured by Bürker chamber.
RESULTS: After the 24 h treatment period, Rosuvastatin significantly inhibited cell proliferation in unchallenged and LPS-challenged cultures by 47.8% and 68.9%, respectively. [1]
METHODS: Nthy-ori 3-1 and B-CPAP cells were treated with Rosuvastatin (12.5-200 µM) for 48-72 h. Apoptosis was detected by TUNEL assay.
RESULTS: The number of apoptotic cells increased in both Nthy ori 3-1 and B-CPAP cells after Rosuvastatin treatment. 12.5 µM concentration of Rosuvastatin treatment resulted in an increase in Apoptotic Index of Nthy ori 3-1 and B-CPAP cells after 48 h. The results were summarized as follows. [2] |
| In vivo | METHODS: To investigate the anti-atherosclerotic effects, Rosuvastatin (5 mg/kg) and candesartan (2.5 mg/kg) were administered by gavage to streptozotocin-induced diabetic Apoe-/- mice once daily for 20 weeks.
RESULTS: In the absence of lipid-lowering effects, Rosuvastatin attenuated plaque area in diabetic mice.The anti-atherosclerotic effect of Rosuvastatin was comparable to that of candesartan. Dual therapy had similar beneficial effects, although it was not superior to monotherapy. [3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 1 mg/mL (2.08 mM), Sonication is recommended.
DMSO : 50 mg/mL (103.83 mM), Sonication is recommended.
|
| Keywords | ZD-4522 | ZD4522 | triglycerides | Rosuvastatin | repolarization | related | QTc | potential | PotassiumChannel | Potassium Channel | low-density | lipoprotein | KcsA | Inhibitor | inhibit | Hsp70 | HMGCR | HMGCoAReductase | HMG-CoA Reductase (HMGCR) | HMG-CoA reductase | HMGCoA Reductase | hERG | gene | durations | cholesterol | cardiac | Autophagy | APDs | action |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
